Evotec (ETR:EVT) Shares Down 0.2% – What’s Next?

Evotec SE (ETR:EVT) fell 0.2% during mid-day trading on Thursday. The company traded as low as €2.78 and last traded at €2.80. 792,348 shares changed hands during trading, a decline of 42% from the average session volume of 1,360,000 shares. The stock had previously closed at €2.81.

Evotec Stock Performance

The firm has a market cap of $519.53 million, a price-to-earnings ratio of -3.03, a PEG ratio of 0.98 and a beta of 1.26. The company has a quick ratio of 2.97, a current ratio of 2.33 and a debt-to-equity ratio of 71.50. The company has a 50 day moving average of €3.30 and a 200 day moving average of €4.30.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.